Calagualine inhibits nuclear transcription factors-κB activated by various inflammatory and tumor promoting agents

Cancer Letters

Volumn 190, Issue 2, 2003, Pages 171-182

  Manna, Sunil K ^a   Bueso Ramos, Carlos ^a   Alvarado, Francisco ^b   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Laboratorio Betania   (Honduras)

Author keywords

Calagualine; Inflammation; LPS; Nuclear transcription factor B; Tumor necrosis factor; Tumor promoters

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CALAGUALINE; I KAPPA B ALPHA; I KAPPA B ALPHA KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN INDUCING KINASE; LIPOPOLYSACCHARIDE; PHORBOL ESTER; PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR PROMOTER; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL SPECIFICITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REPORTER GENE;

FILICOPHYTA;

EID: 0037455955     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00618-3     Document Type: Article

References (61)

1. Farnsworth N.R., Akerele O., Bingel A.S., Soejarto D.D., Guo Z. Medicinal plants in therapy. Bull. World Health Organ. 1985;6365-6981.
2. Reynolds T. Tropical rain forest conservation tied to drug development. J. Natl. Cancer Inst. 83:1991;94-596.
3. Horvath A., Alvarado F., Szocs J., de Alvardo Z.N., Padilla G. Metabolic effects of calagualine, an antitumoral saponine of Polypodium leucotomos. Nature. 214:1967;1256-1258.
4. Bernd A., Ramirez-Bosca A., Huber H., Diaz J., Alperi D., Sewell A., Quintanilla Almagro E., Holzmann H. In vitro studies on the immunomodulating effects of Polypodium leucotomos extract on human leukocyte fractions. Arzneimittelforschung. 45:1995;901-904.
5. Padilla H.C., Lainez H., Pacheco J.A. A new agent (hydrophilic fraction of Polypodium leucotomos) for management of psoriasis. Int. J. Dermatol. 13:1974;276-282.
6. Pineiro Alvarez B. Two years personal experience in anapsos treatment of psoriasis in various clinical forms. Med. Cutanea Ibero-Latino-Am. 11:1983;65-72.
7. Vasange-Tuominen M., Perera-Ivarsson P., Shen J., Bohlin L., Rolfsen W. The fern Polypodium decumanum, used in the treatment of psoriasis, and its fatty acid constituents as inhibitors of leukotriene B4 formation. Prostaglandins Leukot. Essent. Fatty Acids. 50:1994;279-284.
8. Gonzalez S., Pathak M.A., Cuevas J., Villarrubia V.G., Fitzpatrick T.B. Topical or oral administration with an extract of Polypodium leucotomos prevents acute sunburn and psoralen-induced phototoxic reactions as well as depletion of Langerhans cells in human skin. Photodermatol. Photoimmunol. Photomed. 13:1997;50-60.
9. Alcaraz M.V., Pathak M.A., Rius F., Kollias N., Gonzalez S. An extract of Polypodium leucotomos appears to minimize certain photoaging changes in a hairless albino mouse animal model. A pilot study. Photodermatol. Photoimmunol. Photomed. 15:1999;120-126.
10. Mohammad A. Vitiligo repigmentation with Anapsos (Polypodium leucotomos). Int. J. Dermatol. 28:1989;479-482.
11. Rayward J., Villarrubia V.G., Guillen C., Prieto A., Rodriguez-Zapata M., Sada G., Alvarez-Mon M. An extract of the fern Polypodium leucotomos inhibits human peripheral blood mononuclear cells proliferation in vitro. Int. J. Immunopharmacol. 19:1997;9-14.
12. Sempere J.M., Rodrigo C., Campos A., Villalba J.F., Diaz J. Effect of Anapsos (Polypodium leucotomos extract) on in vitro production of cytokines. Br. J. Clin. Pharmacol. 43:1997;85-89.
13. Vasange M., Rolfsen W., Bohlin L. A sulphonoglycolipid from the fern Polypodium decumanum and its effect on the platelet activating-factor receptor in human neutrophils. J. Pharm. Pharmacol. 49:1997;562-566.
14. Tuominen M., Bohlin L., Rolfsen W. Effects of Calaguala and an active principle, adenosine, on platelet activating factor. Planta Med. 58:1992;306-310.
15. Vasange M., Liu B., Welch C.J., Rolfsen W., Bohlin L. The flavonoid constituents of two Polypodium species (Calaguala) and their effect on the elastase release in human neutrophils. Planta Med. 63:1997;511-517.
16. Fernandez-Novoa L., Alvarez X.A., Sempere J.M., Miguel-Hidalgo J.J., Diaz J., Franco-Maside A., Cacabelos R. Effects of anapsos on the activity of the enzyme Cu-Zn-superoxide dismutase in an animal model of neuronal degeneration. Methods Find. Exp. Clin. Pharmacol. 19:1997;99-106.
17. Gonzalez S., Pathak M.A. Inhibition of ultraviolet-induced formation of reactive oxygen species, lipid peroxidation, erythema and skin photosensitization by Polypodium leucotomos. Photodermatol. Photoimmunol. Photomed. 12:1996;45-56.
18. McCutcheon A.R., Roberts T.E., Gibbons E., Ellis S.M., Babiuk L.A., Hancock R.E., Towers G.H. Antiviral screening of British Columbian medicinal plants. J. Ethnopharmacol. 49:1995;101-110.
19. Baldwin A.S. Jr. The NF-κB and IκB proteins: new discoveries and insights. Ann. Rev. Immunol. 14:1996;649-683.
20. Baeuerle P.A., Baichwal V.R. NF-kappa B as a frequent target for immuno-suppressive and anti-inflammatory molecules. Adv. Immunol. 65:1997;111-137.
21. Baichwal V.R., Baeuerle P.A. Apoptosis: activate NF-kappa B or die? Curr. Biol. 7:1997;R94-R96.
22. Lee J.I., Burckart G.J. Nuclear factor kappa B: important transcription factor and therapeutic target. J. Clin. Pharmacol. 38:1998;981-983.
23. Wang C.Y., Mayo M.W., Baldwin A.S. Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science. 274:1996;784-787.
24. Van Antwerp D.J., Martin S.J., Kafri T., Green D.R., Verma I.M. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science. 274:1996;787-789.
25. Giri D.K., Aggarwal B.B. Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J. Biol Chem. 273:1998;14008-14014.
26. Nakshatri H., Bhat-Nakshatri P., Martin D.A., Goulet R.J. Jr, Sledge G.W. Jr. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol. Cell. Biol. 17:1997;3629-3639.
27. Dong G., Chen Z., Kato T., Van Waes C. The host environment promotes the constitutive activation of nuclear factor-kappaB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. Cancer Res. 59:1999;3495-3504.
28. Wang C.Y., Cusack J.C. Jr, Liu R., Baldwin A.S. Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med. 5:1999;412-417.
29. Wang C.Y., Guttridge D.C., Mayo M.W., Baldwin A.S. Jr. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol. Cell. Biol. 19:1999;5923-5929.
30. Sharma H.W., Narayanan R. The NF-κB transcription factor in oncogenesis. Anticancer Res. 16:1996;589-596.
31. Waddick K.G., Uckun F.M. Innovative treatment programs against cancer: II. Nuclear factor-kappaB (NF-kappaB) as a molecular target. Biochem. Pharmacol. 57:1999;9-17.
32. Malinin N.L., Boldin M.P., Kovalenko A.V., Wallach D. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature. 385:1997;540-544.
33. Darnay B.G., Ni J., Moore P.A., Aggarwal B.B. Activation of NF-κB by RANK requires TRAF6 and NF-κB-inducing kinase (NIK): identification of a novel TRAF6 interaction motif. J. Biol. Chem. 274:1999;7724-7731.
34. Chaturvedi M.M., LaPushin R., Aggarwal B.B. Tumor necrosis factor and lymphotoxin: qualitative and quantitative differences in the mediation of early and late cellular responses. J. Biol. Chem. 269:1994;14575-14583.
35. Chaturvedi M.M., Kumar A., Darnay B.G., Chainy G.B.N., Agarwal S., Aggarwal B.B. Sanguinarine (pseudochelerythrine) is a potent inhibitor of NF-κB activation, IκBα phosphorylation, and degradation. J. Biol. Chem. 272:1997;30129-30134.
36. Manna S.K., Aggarwal B.B. α-melanocyte stimulating hormone inhibits the nuclear transcription factor NF-κB activation induced by various inflammatory agents. J. Immunol. 161:1998;2873-2880.
37. Bonizzi G., Piette J., Merville M.P., Bours V. Distinct signal transduction pathways mediate nuclear factor-κB induction by IL-1 beta in epithelial and lymphoid cells. J. Immunol. 159:1997;5264-5272.
38. Finco T.S., Beg A.A., Baldwin A.S. Inducible phosphorylation of I kappa B alpha is not sufficient for its dissociation from NF-kappa B and is inhibited by protease inhibitors. Proc. Natl. Acad. Sci. USA. 91:1994;11884-11888.
39. Mahon T.M., O'Neill L.A. Studies into the effect of the tyrosine kinase inhibitor herbimycin A on NF-kappa B activation in T lymphocytes. Evidence for covalent modification of the p50 subunit. J. Biol. Chem. 270:1995;28557-28564.
40. Natarajan K., Singh S., Burke T.R. Jr, Grunberger D., Aggarwal B.B. Caffeic acid phenethyl ester (CAPE) is a potent and specific inhibitor of activation of nuclear transcription factor NF-κB. Proc. Natl. Acad. Sci. USA. 93:1996;9090-9095.
41. 2 in NF-κB activation by either cytokine in both primary and transformed endothelial cells. J. Biol. Chem. 272:1997;25941-25950.
42. Li N., Karin M. Ionizing radiation and short wavelength UV activate NF-kappaB through two distinct mechanisms. Proc. Natl. Acad. Sci. USA. 95:1998;13012-13017.
43. Israel A. A role for phosphorylation and degradation in the control of NF-kappa B activity. Trends Genet. 11:1995;203-205.
44. Nasuhara Y., Adcock I.M., Catley M., Barnes P.J., Newton R. Differential IkappaB kinase activation and IkappaBalpha degradation by interleukin-1beta and tumor necrosis factor-alpha in human U937 monocytic cells. Evidence for additional regulatory steps in kappaB-dependent transcription. J. Biol. Chem. 274:1999;19965-19972.
45. Hsu H., Shu H.B., Pan M.G., Goeddel D.V. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 84:1996;299-308.
46. Simeonidis S., Stauber D., Chen G., Hendrickson W.A., Thanos D. Mechanisms by which IkappaB proteins control NF-kappaB activity. Proc. Natl. Acad. Sci. USA. 96:1999;49-54.
47. Karin M. How NF-κB is activated: the role of the IκB kinase (IKK) complex. Oncogene. 18:1999;6867-6874.
48. Shimada T., Kawai T., Takeda K., Matsumoto M., Inoue J., Tatsumi Y., Kanamaru A., Akira S. IKK-i, a novel lipopolysaccharide-inducible kinase that is related to IkappaB kinases. Int. Immunol. 11:1999;1357-1362.
49. Hirano M., Osada S., Aoki T., Hirai S., Hosaka M., Inoue J., Ohno S. MEK kinase is involved in tumor necrosis factor alpha-induced NF-kappaB activation and degradation of IkappaB-alpha. J. Biol. Chem. 271:1996;13234-13238.
50. Lallena M.J., Diaz-Meco M.T., Bren G., Paya C.V., Moscat J. Activation of IkappaB kinase beta by protein kinase C isoforms. Mol. Cell. Biol. 19:1999;2180-2188.
51. Ghoda L., Lin X., Greene W.C. The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IkappaBalpha and stimulates its degradation in vitro. J. Biol. Chem. 272:1997;21281-21288.
52. Kumar A., Haque J., Lacoste J., Hiscott J., Williams B.R. Double-stranded RNA-dependent protein kinase activates transcription factor NF-kappa B by phosphorylating I kappa B. Proc. Natl Acad. Sci. USA. 91:1994;6288-6292.
53. Lin X., Cunningham E.T. Jr, Mu Y., Geleziunas R., Greene W.C. The proto-oncogene Cot kinase participates in CD3/CD28 induction of NF-kappaB acting through the NF-kappaB-inducing kinase and IkappaB kinases. Immunity. 10:1999;271-280.
54. Sizemore N., Leung S., Stark G.R. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol. Cell. Biol. 19:1999;4798-4805.
55. Ninomiya-Tsuji J., Kishimoto K., Hiyama A., Inoue J.-I., Cao Z., Matsumoto K. The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signaling pathway. Nature. 398:1999;252-256.
56. Singh S., Aggarwal B.B. Activation of transcription factor NF-κB is suppressed by curcumin (Diferulolylmethane). J. Biol. Chem. 270:1995;24995-25000.
57. Manna S.K., Zhang H.J., Yan T., Oberley L.W., Aggarwal B.B. Overexpression of Mn-superoxide dismutase suppresses TNF induced apoptosis and activation of nuclear transcription factor-κB and activated protein-1. J. Biol. Chem. 273:1998;13245-13254.
58. Manna S.K., Kuo M.T., Aggarwal B.B. Overexpression of γ-glutamyl cysteine synthetase abolishes tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappa B and activator protein-1. Oncogene. 18:1999;4371-4382.
59. Pahl H.L. Activators and target genes of Rel/NF-κB transcription factor. Oncogene. 18:1999;6853-6866.
60. Natarajan K., Manna S.K., Chaturvedi M.M., Aggarwal B.B. Protein tyrosine kinase inhibitors block TNF-induced activation of NF-κB, degradation of IκBα, nuclear translocation of p65 and subsequent gene expression. Arch. Biochem. Biophys. 352:1998;59-70.
61. Kopp E., Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 265:1994;956-959.